Rhythm Pharmaceuticals Inc
$ 88.69
0.66%
17 Apr - close price
- Market Cap 6,016,595,000 USD
- Current Price $ 88.69
- High / Low $ 90.51 / 86.60
- Stock P/E N/A
- Book Value 2.07
- EPS -3.11
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.90 %
- 52 Week High 122.20
- 52 Week Low 55.31
About
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$137.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-02-20 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-22 | 2023-11-07 | 2023-08-01 | 2023-05-02 |
| Reported EPS | -0.73 | -0.82 | -0.75 | -0.81 | -0.72 | -0.73 | -0.69 | -2.35 | -0.7 | -0.76 | -0.82 | -0.92 |
| Estimated EPS | -0.8218 | -0.71 | -0.67 | -2.16 | -0.73 | -0.8 | -0.71 | -2.16 | -0.7 | -0.74 | -0.79 | -0.73 |
| Surprise | 0.0918 | -0.11 | -0.08 | 1.35 | 0.01 | 0.07 | 0.02 | -0.19 | 0 | -0.02 | -0.03 | -0.19 |
| Surprise Percentage | 11.1706% | -15.493% | -11.9403% | 62.5% | 1.3699% | 8.75% | 2.8169% | -8.7963% | 0% | -2.7027% | -3.7975% | -26.0274% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.84 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RYTM
2026-04-17 11:10:37
Needham has reiterated its Buy rating for Rhythm Pharmaceuticals (RYTM.US), maintaining a target price of $130. This decision reflects the firm's continued confidence in the company's prospects. The analyst rating suggests an optimistic outlook for Rhythm Pharmaceuticals' stock performance.
2026-04-16 13:40:11
Goldman Sachs analyst Corinne Johnson has reiterated a Buy rating for Rhythm Pharmaceuticals (RYTM.US) and maintained a target price of $158. According to TipRanks, the analyst has a 50.3% success rate and an average return of 9.1% over the past year. This endorsement highlights continued confidence in Rhythm Pharmaceuticals' stock performance.
2026-04-13 09:10:38
Rhythm Pharmaceuticals (RYTM) has experienced a significant share price pullback, declining 19.5% over three months, despite a strong 41.7% return over the past year. The stock is currently trading at a large discount to analyst price targets and estimated intrinsic value, suggesting it might be undervalued at $84.39 compared to a fair value of $137.27. However, its high P/S ratio of 30.4x, significantly above the peer average of 6.9x, indicates potential overvaluation based on sales metrics, raising concerns about valuation risk.
2026-04-13 01:39:28
Rhythm Pharmaceuticals (RYTM) has experienced a recent share price pullback, declining 19.5% over the past three months, despite a 41.7% return over one year. The article assesses RYTM's valuation, noting it trades at a significant discount to analyst price targets and an estimated intrinsic value of $137.27, primarily due to upcoming potential regulatory approvals and intellectual property protection for its lead asset. However, it also highlights valuation risks, including the company's high P/S ratio of 30.4x compared to a peer average of 6.9x, and advises investors to consider these factors alongside future growth expectations.
2026-04-12 10:09:57
Rhythm Pharmaceuticals (RYTM) has seen a significant 48.9% share price gain over the past year. A Discounted Cash Flow (DCF) analysis suggests the stock is 79.8% undervalued, estimating an intrinsic value of $426.55 per share against its current price of US$86.13. However, its Price-to-Sales (P/S) ratio of 30.99x is above the industry average, indicating it might be overvalued based on revenue multiples compared to peers.
2026-04-11 21:40:11
Wall Street Zen has upgraded Rhythm Pharmaceuticals (RYTM) from a "sell" to a "hold" rating, while the broader analyst consensus remains a "Moderate Buy" with an average price target of $131.13. Despite the company slightly beating quarterly earnings expectations, it remains unprofitable, and insiders have been selling shares even as institutional investors increased their holdings. Rhythm Pharmaceuticals is a clinical-stage biotechnology company focusing on therapies for rare genetic diseases of obesity.
